Angitia Biopharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of AGA2118 for the Treatment of Osteoporosis
November 04, 2024 07:30 ET
|
Angitia Incorporated Limited
WOODLAND HILLS, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for...
Angitia Biopharmaceuticals to Present Data on AGA2118 for Osteoporosis at ASBMR 2024
September 16, 2024 07:30 ET
|
Angitia Biopharmaceuticals
Angitia announces multiple presentations at ASBMR.
Entera’s EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual Meeting - Key SABRE Update Also Expected
August 01, 2024 08:30 ET
|
Entera Bio Ltd.
JERUSALEM, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides and therapeutic proteins, today...
Wake Radiology UNC Rex Healthcare’s Advanced Screening Bone Density Scan Technology Provides New Early-Warning Information to Patients About Osteoporosis Risk
July 22, 2024 09:30 ET
|
Wake Radiology UNC Rex Healthcare
Raleigh, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- Wake Radiology is the first outpatient provider in the Triangle to offer a standard bone density scan with trabecular bone score (TBS). These...
Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates
May 10, 2024 16:10 ET
|
Entera Bio Ltd.
JERUSALEM, May 10, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today...
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
April 08, 2024 08:30 ET
|
Entera Bio Ltd.
JERUSALEM, April 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today that data from the...
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months
March 26, 2024 08:30 ET
|
Entera Bio Ltd.
JERUSALEM, March 26, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides, announced today that The American...
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
March 08, 2024 16:05 ET
|
Entera Bio Ltd.
JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results...
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
March 04, 2024 08:30 ET
|
Entera Bio Ltd.
JERUSALEM, March 04, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today that it received...
Osteoporosis Drugs Market is Projected to Develop at a CAGR of 3.5% from 2023 to 2033 | Persistence Market Research
January 16, 2024 03:00 ET
|
Persistence Market Research
New York, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Market Overview: The Osteoporosis Drugs Market is a rapidly evolving sector within the pharmaceutical industry, primarily driven by the growing aging...